319 related articles for article (PubMed ID: 20466987)
1. Aldose reductase and cardiovascular diseases, creating human-like diabetic complications in an experimental model.
Ramasamy R; Goldberg IJ
Circ Res; 2010 May; 106(9):1449-58. PubMed ID: 20466987
[TBL] [Abstract][Full Text] [Related]
2. Aldose Reductase: An Emerging Target for Development of Interventions for Diabetic Cardiovascular Complications.
Jannapureddy S; Sharma M; Yepuri G; Schmidt AM; Ramasamy R
Front Endocrinol (Lausanne); 2021; 12():636267. PubMed ID: 33776930
[TBL] [Abstract][Full Text] [Related]
3. Human aldose reductase expression accelerates atherosclerosis in diabetic apolipoprotein E-/- mice.
Vedantham S; Noh H; Ananthakrishnan R; Son N; Hallam K; Hu Y; Yu S; Shen X; Rosario R; Lu Y; Ravindranath T; Drosatos K; Huggins LA; Schmidt AM; Goldberg IJ; Ramasamy R
Arterioscler Thromb Vasc Biol; 2011 Aug; 31(8):1805-13. PubMed ID: 21636809
[TBL] [Abstract][Full Text] [Related]
4. Aldose reductase expression as a risk factor for cataract.
Snow A; Shieh B; Chang KC; Pal A; Lenhart P; Ammar D; Ruzycki P; Palla S; Reddy GB; Petrash JM
Chem Biol Interact; 2015 Jun; 234():247-53. PubMed ID: 25541468
[TBL] [Abstract][Full Text] [Related]
5. Aldose reductase-deficient mice are protected from delayed motor nerve conduction velocity, increased c-Jun NH2-terminal kinase activation, depletion of reduced glutathione, increased superoxide accumulation, and DNA damage.
Ho EC; Lam KS; Chen YS; Yip JC; Arvindakshan M; Yamagishi S; Yagihashi S; Oates PJ; Ellery CA; Chung SS; Chung SK
Diabetes; 2006 Jul; 55(7):1946-53. PubMed ID: 16804062
[TBL] [Abstract][Full Text] [Related]
6. [Aldose reductase in the polyol pathway: a potential target for the therapeutic intervention of diabetic complications].
Nishimura-Yabe C
Nihon Yakurigaku Zasshi; 1998 Mar; 111(3):137-45. PubMed ID: 9583077
[TBL] [Abstract][Full Text] [Related]
7. Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitor.
Yagihashi S; Yamagishi SI; Wada Ri R; Baba M; Hohman TC; Yabe-Nishimura C; Kokai Y
Brain; 2001 Dec; 124(Pt 12):2448-58. PubMed ID: 11701599
[TBL] [Abstract][Full Text] [Related]
8. Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice.
Vikramadithyan RK; Hu Y; Noh HL; Liang CP; Hallam K; Tall AR; Ramasamy R; Goldberg IJ
J Clin Invest; 2005 Sep; 115(9):2434-43. PubMed ID: 16127462
[TBL] [Abstract][Full Text] [Related]
9. Aldose reductase protects against early atherosclerotic lesion formation in apolipoprotein E-null mice.
Srivastava S; Vladykovskaya E; Barski OA; Spite M; Kaiserova K; Petrash JM; Chung SS; Hunt G; Dawn B; Bhatnagar A
Circ Res; 2009 Oct; 105(8):793-802. PubMed ID: 19729598
[TBL] [Abstract][Full Text] [Related]
10. Exclusion of aldose reductase as a mediator of ERG deficits in a mouse model of diabetic eye disease.
Samuels IS; Lee CA; Petrash JM; Peachey NS; Kern TS
Vis Neurosci; 2012 Nov; 29(6):267-74. PubMed ID: 23101909
[TBL] [Abstract][Full Text] [Related]
11. Aldose reductase, oxidative stress and diabetic cardiovascular complications.
Vedantham S; Ananthakrishnan R; Schmidt AM; Ramasamy R
Cardiovasc Hematol Agents Med Chem; 2012 Sep; 10(3):234-40. PubMed ID: 22632267
[TBL] [Abstract][Full Text] [Related]
12. Genetic deficiency of aldose reductase counteracts the development of diabetic nephropathy in C57BL/6 mice.
Liu H; Luo Y; Zhang T; Zhang Y; Wu Q; Yuan L; Chung SS; Oates PJ; Yang JY
Diabetologia; 2011 May; 54(5):1242-51. PubMed ID: 21267539
[TBL] [Abstract][Full Text] [Related]
13. Elevated Fructose and Uric Acid Through Aldose Reductase Contribute to Experimental and Human Alcoholic Liver Disease.
Wang M; Chen WY; Zhang J; Gobejishvili L; Barve SS; McClain CJ; Joshi-Barve S
Hepatology; 2020 Nov; 72(5):1617-1637. PubMed ID: 32086945
[TBL] [Abstract][Full Text] [Related]
14. A spontaneously immortalized Schwann cell line from aldose reductase-deficient mice as a useful tool for studying polyol pathway and aldehyde metabolism.
Niimi N; Yako H; Takaku S; Kato H; Matsumoto T; Nishito Y; Watabe K; Ogasawara S; Mizukami H; Yagihashi S; Chung SK; Sango K
J Neurochem; 2018 Mar; 144(6):710-722. PubMed ID: 29238976
[TBL] [Abstract][Full Text] [Related]
15. Sorbinil, an Aldose Reductase Inhibitor, in Fighting Against Diabetic Complications.
Huang Q; Liu Q; Ouyang D
Med Chem; 2019; 15(1):3-7. PubMed ID: 29792152
[TBL] [Abstract][Full Text] [Related]
16. Aldose Reductase Mediates NLRP3 Inflammasome-Initiated Innate Immune Response in Hyperglycemia-Induced Thp1 Monocytes and Male Mice.
Pal PB; Sonowal H; Shukla K; Srivastava SK; Ramana KV
Endocrinology; 2017 Oct; 158(10):3661-3675. PubMed ID: 28938395
[TBL] [Abstract][Full Text] [Related]
17. More severe type 2 diabetes-associated ischemic stroke injury is alleviated in aldose reductase-deficient mice.
Yeung CM; Lo AC; Cheung AK; Chung SS; Wong D; Chung SK
J Neurosci Res; 2010 Jul; 88(9):2026-34. PubMed ID: 20143423
[TBL] [Abstract][Full Text] [Related]
18. Aldose Reductase and the Polyol Pathway in Schwann Cells: Old and New Problems.
Niimi N; Yako H; Takaku S; Chung SK; Sango K
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33494154
[TBL] [Abstract][Full Text] [Related]
19. Aldose reductase inhibition ameliorates the detrimental effect of estrogen replacement therapy on neuropathology in diabetic rats subjected to transient forebrain ischemia.
Shen B; Vetri F; Mao L; Xu HL; Paisansathan C; Pelligrino DA
Brain Res; 2010 Jun; 1342():118-26. PubMed ID: 20417192
[TBL] [Abstract][Full Text] [Related]
20. Aldose reductase inhibition: emerging drug target for the treatment of cardiovascular complications.
Reddy AB; Ramana KV
Recent Pat Cardiovasc Drug Discov; 2010 Jan; 5(1):25-32. PubMed ID: 19886861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
